Newsroom

Largest study of its kind provides new insights on lymphoma biology to guide clinical approaches Researchers identified three subgroups with differential benefit from CD19 CAR T cell therapy Study points to opportunities for alternative approaches to treat patients who do not benefit from CAR T cell therapies

HOUSTON, JUNE 18, 2025 ― In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center...

Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes, lymph nodes. First-in-class antibody-drug conjugate, pivekimab sunirine (PVEK), was safe and effective. PVEK achieved an overall response rate of 85% and complete response rate of 70% as frontline treatment in newly diagnosed patients with BPDCN. Findings suggest this treatment should be considered...